Pacific Biosciences Of California (PACB) Net Cash Flow Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -31.84% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 76.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -394.13% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | -335.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -335.73% |
| Dec 31, 2025 | 130.78% |
| Sep 30, 2025 | 107.71% |
| Jun 30, 2025 | -118.26% |
| Mar 31, 2025 | 103.04% |
| Dec 31, 2024 | 89.01% |
| Sep 30, 2024 | -112.24% |
| Jun 30, 2024 | 115.46% |
| Mar 31, 2024 | -459.25% |
| Dec 31, 2023 | -1,096.02% |
| Sep 30, 2023 | 3,033.48% |
| Jun 30, 2023 | -20.48% |
| Mar 31, 2023 | 190.50% |
| Dec 31, 2022 | -41.60% |
| Jun 30, 2022 | 74.58% |
| Mar 31, 2022 | -103.73% |
| Dec 31, 2021 | 169.60% |
| Jun 30, 2021 | -1,720.29% |
| Mar 31, 2021 | 2,068.44% |
| Dec 31, 2020 | 479.49% |